Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, which manifests clinically as progressive weakness. Although several epidemiological studies have found an association between traumatic brain injury (TBI) and ALS, there is not a consensus on whether TBI is an ALS risk factor. It may be that it can cause ALS in a subset of susceptible patients, based on a history of repetitive mild TBI and genetic predisposition. This cannot be determined based on clinical observational studies alone. Better preclinical models are necessary to evaluate the effects of TBI on ALS onset and progression. To date, only a small number of preclinical studies have been performed, mainly in the superoxide dismutase 1 transgenic rodents, which, taken together, have mixed results and notable methodological limitations. The more recent incorporation of additional animal models such as Drosophila flies, as well as patient-induced pluripotent stem cell-derived neurons, should facilitate a better understanding of a potential functional interaction between TBI and ALS.
Original language | English (US) |
---|---|
Pages (from-to) | 1174-1185 |
Number of pages | 12 |
Journal | Journal of neurophysiology |
Volume | 122 |
Issue number | 3 |
DOIs | |
State | Published - 2019 |
Funding
We are grateful to the following funding sources: US National Institutes of Health (NIH)/National Institute on Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) R01NS104219 (E. Kiskinis), NIH/NINDS grants R21NS098129 (J. D. Finan), R21NS107761 (E. Kiskinis), R21NS111248 (E. Kiskinis), Muscular Dystrophy Association (E. Kiskinis), the Les Turner ALS Foundation (E. Kiskinis), the Craig H. Nielsen Foundation (C. K. Franz), and the Foundation for Physical Medicine and Rehabilitation (C. K. Franz). C. K. Franz is a member of the Shirley Ryan AbilityLab’s Center for Translational Biomedicine, Northwestern’s Skin Disease Research Center, as well as a physician in the Lois Insolia ALS Clinic at the Les Turner ALS Center. E. Kiskinis is a member of the Simpson Querrey Institute for BioNanotechnology and a Les Turner ALS Research Center Investigator.
Keywords
- Amyotrophic lateral sclerosis (ALS)
- Concussion
- Induced pluripotent stem cell (iPSC)
- Superoxide dismutase 1 (SOD1)
- TAR DNA-binding protein 43 (TDP-43)
- Traumatic brain injury (TBI)
ASJC Scopus subject areas
- Physiology
- General Neuroscience